Overview
Keeping Up the Pace in IBD: Adaptive Learning to Optimize Therapeutic Decision-Making for Patients with UC and CD
Personalized Learning Platform powered by ACHL AdaptED®
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivityCME/CE is no longer available for this activity
Whether you’re a specialist looking for advanced-level learning around optimally managing Crohn’s disease and ulcerative colitis, a generalist needing to expand your knowledge of inflammatory bowel disease (IBD), or an allied healthcare professional wanting to support patients, don’t miss the opportunity to participate in this one-of-a-kind educational experience. In this adaptive learning activity, experience education uniquely tailored to your individual needs.
Hear from our expert faculty about the advantages of the ACHL AdaptED® learning experience:
Hear from our expert faculty about the advantages of the ACHL AdaptED® learning experience:
This activity is intended for IBD specialists, general gastroenterologists, and NPs and PAs who manage patients with IBD.
Management of ulcerative colitis and Crohn’s disease is complicated due to their complex pathophysiology. As evidence continues to build and guide treatment paradigms, clinicians need to be aware of the new and emerging treatment options and skilled in the art of tailoring therapy to an individual patient’s needs, ongoing symptoms, and quality of life (QoL). In this dynamic platform, learners engage in questions across multiple topics to access insights through current data, key takeaways, and expert guidance, in order to optimize treatment of these chronic autoimmune disorders.
Upon completion of this activity, participants will be able to:
• Outline the importance of optimizing quality of life for patients with IBD
• Assess the clinical data and potential roles of IBD therapies recently approved and in late-stage development
• Differentiate newer IBD therapies from the older, conventional agents
• Incorporate treat to target (T2T) strategies into the management of patients with IBD
• Review the latest evidence with novel biomarkers for IBD care
• Outline the importance of optimizing quality of life for patients with IBD
• Assess the clinical data and potential roles of IBD therapies recently approved and in late-stage development
• Differentiate newer IBD therapies from the older, conventional agents
• Incorporate treat to target (T2T) strategies into the management of patients with IBD
• Review the latest evidence with novel biomarkers for IBD care
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Benjamin Cohen, MD
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic Foundation
Cleveland, OH
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic Foundation
Cleveland, OH
Neilanjan Nandi, MD
Associate Professor of Clinical Medicine
Department of Medicine, Division of Gastroenterology & Hepatology
University of Pennsylvania
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Benjamin Cohen, MD
Advisor or Review Panel member: Celgene-Bristol Myers Squibb, Lilly, Pfizer, Takeda
Consultant (Occasional): Abbvie
Consultant (Retained): Target RWE
Grant/Research Support recipient: Pfizer
Speaker Bureau: Abbvie
Neilanjan Nandi, MD
Advisor or Review Panel member: Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors for treatment of acute severe ulcerative colitis
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit for each module, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on each posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. Credit will be submitted on the first business day of each month.
MIPS Improvement Activity
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
